Daiichi Sankyo Co. Ltd., of Tokyo, and Agendia BV, of Amsterdam, inked an oncology drug development and personalized medicine deal calling for Agendia's oncology biomarker technology to be used in the assessment of pharmaceuticals now being researched in certain Daiichi clinical trials.